Literature DB >> 30610085

Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Nisha R Pawar1,2, Marguerite S Buzza1,2,3, Toni M Antalis4,2,3.   

Abstract

Pericellular proteolysis provides a significant advantage to developing tumors through the ability to remodel the extracellular matrix, promote cell invasion and migration, and facilitate angiogenesis. Recent advances demonstrate that pericellular proteases can also n class="Chemical">communicate directly to cells by activation of a unique group of transmembrane G-protein-coupled receptors (GPCR) known as protease-activated receptors (PAR). In this review, we discuss the specific roles of one of four mammalian PARs, namely PAR-2, which is overexpressed in advanced stage tumors and is activated by trypsin-like serine proteases that are highly expressed or otherwise dysregulated in many cancers. We highlight recent insights into the ability of different protease agonists to bias PAR-2 signaling and the newly emerging evidence for an interplay between PAR-2 and membrane-anchored serine proteases, which may co-conspire to promote tumor progression and metastasis. Interfering with these pathways might provide unique opportunities for the development of new mechanism-based strategies for the treatment of advanced and metastatic cancers. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30610085      PMCID: PMC6335149          DOI: 10.1158/0008-5472.CAN-18-1745

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  152 in total

1.  Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase.

Authors:  Stine Friis; Sine Godiksen; Jette Bornholdt; Joanna Selzer-Plon; Hanne Borger Rasmussen; Thomas H Bugge; Chen-Yong Lin; Lotte K Vogel
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

2.  Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain.

Authors:  Ming-Shyue Lee; I-Chu Tseng; Youhong Wang; Ken-ichi Kiyomiya; Michael D Johnson; Robert B Dickson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2007-03-07       Impact factor: 4.249

3.  Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells.

Authors:  K Shigemasa; L J Underwood; J Beard; H Tanimoto; K Ohama; T H Parmley; T J O'Brien
Journal:  J Soc Gynecol Investig       Date:  2000 Nov-Dec

4.  A mouse serine protease TESP5 is selectively included into lipid rafts of sperm membrane presumably as a glycosylphosphatidylinositol-anchored protein.

Authors:  Arata Honda; Kazuo Yamagata; Shin Sugiura; Katsuto Watanabe; Tadashi Baba
Journal:  J Biol Chem       Date:  2002-02-22       Impact factor: 5.157

5.  Local protease signaling contributes to neural tube closure in the mouse embryo.

Authors:  Eric Camerer; Adrian Barker; Daniel N Duong; Rajkumar Ganesan; Hiroshi Kataoka; Ivo Cornelissen; Molly R Darragh; Arif Hussain; Yao-Wu Zheng; Yoga Srinivasan; Christopher Brown; Shan-Mei Xu; Jean B Regard; Chen-Yong Lin; Charles S Craik; Daniel Kirchhofer; Shaun R Coughlin
Journal:  Dev Cell       Date:  2010-01-19       Impact factor: 12.270

Review 6.  Matriptase and its putative role in cancer.

Authors:  K Uhland
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

7.  A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Sine Godiksen; Diane E Peters; Chen-Yong Lin; Lotte K Vogel; Thomas H Bugge
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

8.  Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.

Authors:  Roman Szabo; Katiuchia Uzzun Sales; Peter Kosa; Natalia A Shylo; Sine Godiksen; Karina K Hansen; Stine Friis; J Silvio Gutkind; Lotte K Vogel; Edith Hummler; Eric Camerer; Thomas H Bugge
Journal:  PLoS Genet       Date:  2012-08-30       Impact factor: 5.917

9.  The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.

Authors:  Ayala Tamir; Anju Gangadharan; Sakshi Balwani; Takemi Tanaka; Ushma Patel; Ahmed Hassan; Stephanie Benke; Agnieszka Agas; Joseph D'Agostino; Dayoung Shin; Sunghoon Yoon; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Ovarian Res       Date:  2016-03-31       Impact factor: 4.234

10.  The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.

Authors:  Shang-Ru Wu; Chen-Hsin Teng; Ya-Ting Tu; Chun-Jung Ko; Tai-Shan Cheng; Shao-Wei Lan; Hsin-Ying Lin; Hsin-Hsien Lin; Hsin-Fang Tu; Pei-Wen Hsiao; Hsiang-Po Huang; Chung-Hsin Chen; Ming-Shyue Lee
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

View more
  12 in total

1.  Iterative, multiplexed CRISPR-mediated gene editing for functional analysis of complex protease gene clusters.

Authors:  LuLu K Callies; Daniel Tadeo; Jan Simper; Thomas H Bugge; Roman Szabo
Journal:  J Biol Chem       Date:  2019-09-09       Impact factor: 5.157

2.  Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.

Authors:  Candy M Rivas; Hillary V Schiff; Aubin Moutal; Rajesh Khanna; Pawel R Kiela; Gregory Dussor; Theodore J Price; Josef Vagner; Kathryn A DeFea; Scott Boitano
Journal:  Biochem Biophys Res Commun       Date:  2021-12-29       Impact factor: 3.575

3.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

4.  Treatment of ovarian cancer with modified anthrax toxin.

Authors:  Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-02       Impact factor: 12.779

5.  Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation.

Authors:  Yuhong Jiang; Xin Zhuo; Xiujuan Fu; Yue Wu; Canquan Mao
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 6.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 7.  Pancreatic Proteolytic Enzymes and Cancer: New Support for an Old Theory.

Authors:  Linda L Isaacs
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

8.  Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019.

Authors:  Saravanan Subramaniam; Wolfram Ruf; Markus Bosmann
Journal:  Br J Pharmacol       Date:  2021-07-07       Impact factor: 8.739

Review 9.  Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis.

Authors:  Kjetil Søreide; Marcus Roalsø; Jan Rune Aunan
Journal:  J Pancreat Cancer       Date:  2020-02-06

10.  Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer.

Authors:  Qianfei Liu; Jianbo He; Ruiling Ning; Liping Tan; Aiping Zeng; Shaozhang Zhou
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.